Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management ofHER2+breast cancer and examining the potential use of at-home administration.
Data from the following clinical trial are discussed:
Patient preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab and trastuzumab in pts with HER2-positive early breast cancer: Interim analysis of the open-label, randomized crossover PHranceSCa study. (O’Shaughnessy J et al. 2020 ESMO annual meeting. Abstract 80O.)